{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T15:40:15Z","timestamp":1733326815505,"version":"3.30.1"},"reference-count":50,"publisher":"American Society of Tropical Medicine and Hygiene","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,4]]},"abstract":"<jats:title>ABSTRACT.<\/jats:title>\n<jats:p>The effectiveness of treatment of cutaneous leishmaniasis (CL) in rural settings remains underexplored. This study assessed the effectiveness of standard antileishmanial treatments using a community-based approach supported by mobile health (mHealth) in three rural areas of Colombia. From January 2018 to September 2021, we assessed treatment outcomes, adherence, and adverse drug reactions in CL patients, with the support of the Guaral+ST app. Treatment decisions were made by providers at health facilities at each site in accordance with national guidelines, whereas treatment follow-up and presumptive case identification were made by trained community leaders and health agents at the community level. In total, 231 participants received antileishmanial treatment (63 received miltefosine, 110 meglumine antimoniate, and 58 pentamidine). Disease presentation was mild (median number of lesions = 1, interquartile range [IQR]: 1\u20132) and of short duration (1.5 months, IQR: 1\u20133). The strategy yielded information on the therapeutic outcomes in 81% of study participants. Effectiveness, measured as the proportion of cure at 90 to 180\u2009days, was 86.3% (95% CI: 73.3\u201393.48) for miltefosine; 77.6% (67.5\u201385.3) for meglumine antimoniate, and 73.1% (59.0\u201383.6) for pentamidine. The effectiveness of pentamidine in children \u226410\u2009years old was 79.4% (61.6\u201390.3). This is one of the few reports of effectiveness of pentamidine in children with prospective data collection in the Americas. Adverse drug reactions occurred in 32% of patients, most frequently with meglumine antimoniate. Our findings demonstrate that standard antileishmanial treatments are effective in rural areas where the disease is endemic and that mHealth has a pivotal role in improving patient follow-up and data collection on therapeutic outcomes.<\/jats:p>","DOI":"10.4269\/ajtmh.24-0367","type":"journal-article","created":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T14:54:36Z","timestamp":1728399276000},"page":"1206-1214","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness of Antileishmanial Treatments in Three Endemic Areas of Colombia: A Community-Based Cohort Study"],"prefix":"10.4269","volume":"111","author":[{"given":"Mar\u00eda del Mar","family":"Castro","sequence":"first","affiliation":[{"name":"Centro Internacional de Entrenamiento e Investigaciones M\u00e9dicas (CIDEIM), Cali, Colombia;"},{"name":"Universidad Icesi, Cali, Colombia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandra Mar\u00eda","family":"Del Castillo","sequence":"additional","affiliation":[{"name":"Centro Internacional de Entrenamiento e Investigaciones M\u00e9dicas (CIDEIM), Cali, Colombia;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth Mabel","family":"Castillo","sequence":"additional","affiliation":[{"name":"Centro Internacional de Entrenamiento e Investigaciones M\u00e9dicas (CIDEIM), Cali, Colombia;"},{"name":"Universidad Icesi, Cali, Colombia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Cossio","sequence":"additional","affiliation":[{"name":"Centro Internacional de Entrenamiento e Investigaciones M\u00e9dicas (CIDEIM), Cali, Colombia;"},{"name":"Universidad Icesi, Cali, Colombia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Casta\u00f1o Grajales","sequence":"additional","affiliation":[{"name":"Centro Internacional de Entrenamiento e Investigaciones M\u00e9dicas (CIDEIM), Cali, Colombia;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yeison","family":"Guti\u00e9rrez","sequence":"additional","affiliation":[{"name":"Centro Internacional de Entrenamiento e Investigaciones M\u00e9dicas (CIDEIM), Cali, Colombia;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neal","family":"Alexander","sequence":"additional","affiliation":[{"name":"Centro Internacional de Entrenamiento e Investigaciones M\u00e9dicas (CIDEIM), Cali, Colombia;"},{"name":"Universidad Icesi, Cali, Colombia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2795","reference":[{"year":"2022","series-title":"Leishmaniasis. Informe Epidemiologico de las Americas","key":"b1"},{"year":"2022","key":"b2"},{"key":"b3","series-title":"BMC Int Health Hum Rights","first-page":"12","article-title":"Leishmaniasis patients\u2019 pilgrimage to access health care in rural Bolivia: A qualitative study using human rights to health approach","volume":"19","author":"Eid","year":"2019"},{"key":"b4","series-title":"BMC Infect Dis","first-page":"302","article-title":"Barriers to cutaneous leishmaniasis care faced by indigenous communities of rural areas in Colombia: A qualitative study","volume":"22","author":"Bautista-Gomez","year":"2022"},{"key":"b5","series-title":"Am J Trop Med Hyg","first-page":"187","article-title":"Treatment failure in children in a randomized clinical trial with 10 and 20 days of meglumine antimonate for cutaneous leishmaniasis due to Leishmania viannia species","volume":"64","author":"Palacios","year":"2001"},{"key":"b6","series-title":"PLoS Negl Trop Dis","first-page":"e0005515","article-title":"Risk factors for therapeutic failure to meglumine antimoniate and miltefosine in adults and children with cutaneous leishmaniasis in Colombia: A cohort study","volume":"11","author":"Castro","year":"2017"},{"key":"b7","series-title":"PLoS Negl Trop Dis","first-page":"e912","article-title":"Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: A randomized and controlled trial","volume":"4","author":"Machado","year":"2010"},{"key":"b8","series-title":"Am J Trop Med Hyg","first-page":"210","article-title":"Efficacy of miltefosine for Bolivian cutaneous leishmaniasis","volume":"78","author":"Soto","year":"2008"},{"key":"b9","series-title":"Am J Trop Med Hyg","first-page":"255","article-title":"Randomized controlled clinical trial to access efficacy and safety of miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania (Viannia) guyanensis in Manaus, Brazil","volume":"84","author":"Chrusciak-Talhari","year":"2011"},{"key":"b10","series-title":"PLoS Negl Trop Dis","first-page":"e0006141","article-title":"Harmonized clinical trial methodologies for localized cutaneous leishmaniasis and potential for extensive network with capacities for clinical evaluation","volume":"12","author":"Olliaro","year":"2018"},{"key":"b11","series-title":"PLoS Negl Trop Dis","first-page":"e0005868","article-title":"SisLeish: A multi-country standardized information system to monitor the status of leishmaniasis in the Americas","volume":"11","author":"Maia-Elkhoury","year":"2017"},{"key":"b12","series-title":"PLoS Negl Trop Dis","first-page":"e0011029","article-title":"Cutaneous leishmaniasis treatment and therapeutic outcomes in special populations: A collaborative retrospective study","volume":"17","author":"Castro","year":"2023"},{"key":"b13","series-title":"Am J Trop Med Hyg","first-page":"662","article-title":"Sensitivity and specificity of the remote evaluation of therapeutic response in cutaneous leishmaniasis using photographs from a mobile application","volume":"107","author":"Del Castillo","year":"2022"},{"key":"b14","series-title":"PLoS Negl Trop Dis","first-page":"e0011180","article-title":"Randomized trial evaluating an mHealth intervention for the early community-based detection and follow-up of cutaneous leishmaniasis in rural Colombia","volume":"17","author":"Castillo","year":"2023"},{"key":"b15","series-title":"Am J Trop Med Hyg","first-page":"778","article-title":"mHealth monitoring of treatment of cutaneous leishmaniasis patients: A community-based implementation study","volume":"109","author":"Cossio","year":"2023"},{"year":"2018","key":"b16"},{"key":"b17","series-title":"PLoS Negl Trop Dis","first-page":"e0009291","article-title":"Diagnostic performance of a recombinant polymerase amplification test-lateral flow (RPA-LF) for cutaneous leishmaniasis in an endemic setting of Colombia","volume":"15","author":"Cossio","year":"2021"},{"year":"2019","author":"Cossio","key":"b18"},{"key":"b19","series-title":"Acta Trop","first-page":"106122","article-title":"Integration of phlebotomine ecological niche modelling, and mapping of cutaneous leishmaniasis surveillance data, to identify areas at risk of under-estimation","volume":"224","author":"Ocampo","year":"2021"},{"year":"2018","key":"b20"},{"year":"2018","key":"b21"},{"key":"b22","series-title":"Am J Trop Med Hyg","first-page":"270","article-title":"Identification and distribution of New World Leishmania species characterized by serodeme analysis using monoclonal antibodies","volume":"36","author":"Grimaldi","year":"1987"},{"key":"b23","series-title":"Am J Trop Med Hyg","first-page":"738","article-title":"Heterogeneity, geographic distribution, and pathogenicity of serodemes of Leishmania viannia in Colombia","volume":"66","author":"Saravia","year":"2002"},{"key":"b24","series-title":"PLoS Negl Trop Dis","first-page":"e2130","article-title":"Methodology of clinical trials aimed at assessing interventions for cutaneous leishmaniasis","volume":"7","author":"Olliaro","year":"2013"},{"year":"2018","series-title":"Lineamientos para la Atenci\u00f3n Cl\u00ednica de Leishmaniasis en Colombia. Transmisibles","key":"b25"},{"key":"b26","series-title":"Pathogens","first-page":"378","article-title":"Pentoxifylline in the treatment of cutaneous leishmaniasis: A randomized clinical trial in Colombia","volume":"11","author":"Castro","year":"2022"},{"key":"b27","series-title":"J Infect Dis","first-page":"684","article-title":"Noninferiority of miltefosine versus meglumine antimoniate for cutaneous leishmaniasis in children","volume":"205","author":"Rubiano","year":"2012"},{"key":"b28","series-title":"Antimicrob Agents Chemother","first-page":"e02198-16","article-title":"Pharmacokinetics of miltefosine in children and adults with cutaneous leishmaniasis","volume":"61","author":"Castro","year":"2017"},{"key":"b29","series-title":"BMC Res Notes","first-page":"213","article-title":"Data management plan for a community-level study of the hidden burden of cutaneous leishmaniasis in Colombia","volume":"14","author":"Oviedo Sarmiento","year":"2021"},{"key":"b30","series-title":"J Surv Stat Methodol","first-page":"484","article-title":"Evaluating confidence interval methods for binomial proportions in clustered surveys","volume":"3","author":"Dean","year":"2015"},{"key":"b31","series-title":"Am J Trop Med Hyg","first-page":"574","article-title":"Association of treatment of American cutaneous leishmaniasis prior to ulcer development with high rate of failure in northeastern Brazil","volume":"80","author":"Unger","year":"2009"},{"key":"b32","series-title":"Rev Inst Med Trop Sao Paulo","first-page":"375","article-title":"Montenegro skin test and age of skin lesion as predictors of treatment failure in cutaneous leishmaniasis","volume":"56","author":"Antonio Lde","year":"2014"},{"year":"2022","series-title":"Guideline for the Treatment of Leishmaniasis in the Americas","key":"b33"},{"key":"b34","series-title":"PLoS Negl Trop Dis","first-page":"e0006986","article-title":"Interventions to treat cutaneous leishmaniasis in children: A systematic review","volume":"12","author":"Uribe-Restrepo","year":"2018"},{"key":"b35","series-title":"Clin Exp Dermatol","first-page":"913","article-title":"Using pentamidine to treat cutaneous leishmaniasis in children: A 10-year study in French Guiana","volume":"48","author":"Heleine","year":"2023"},{"key":"b36","series-title":"Clin Infect Dis","first-page":"e2465","article-title":"A double-blind, randomized trial to evaluate miltefosine and topical granulocyte macrophage colony-stimulating factor in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil","volume":"73","author":"Machado","year":"2021"},{"key":"b37","series-title":"Clin Infect Dis","first-page":"e2457","article-title":"Efficacy and tolerability of miltefosine in the treatment of cutaneous leishmaniasis","volume":"73","author":"Ware","year":"2021"},{"key":"b38","series-title":"Clin Infect Dis","first-page":"574","article-title":"A randomized, controlled, noninferiority, multicenter trial of systemic vs intralesional treatment with meglumine antimoniate for cutaneous leishmaniasis in Brazil","volume":"77","author":"Lyra","year":"2023"},{"key":"b39","series-title":"Am J Trop Med Hyg","first-page":"1182","article-title":"Treatment of Bolivian Leishmania braziliensis cutaneous and mucosal leishmaniasis","volume":"106","author":"Soto","year":"2022"},{"key":"b40","series-title":"Travel Med Infect Dis","first-page":"31","article-title":"Use of the intramuscular route to administer pentamidine isethionate in Leishmania guyanensis cutaneous leishmaniasis increases the risk of treatment failure","volume":"24","author":"Christen","year":"2018"},{"key":"b41","series-title":"Ann Trop Med Parasitol","first-page":"331","article-title":"Influence of clinical presentation on the efficacy of a short course of pentamidine in the treatment of cutaneous leishmaniasis in French Guiana","volume":"95","author":"Nacher","year":"2001"},{"key":"b42","series-title":"Ann Trop Med Parasitol","first-page":"307","article-title":"Comparison between one and two injections of pentamidine isethionate, at 7 mg\/kg in each injection, in the treatment of cutaneous leishmaniasis in French Guiana","volume":"100","author":"Roussel","year":"2006"},{"key":"b43","series-title":"Clin Infect Dis","first-page":"417","article-title":"Evaluation of pentamidine for the treatment of cutaneous leishmaniasis in Colombia","volume":"16","author":"Soto-Mancipe","year":"1993"},{"key":"b44","series-title":"An Bras Dermatol","first-page":"807","article-title":"Efficacy and safety of a single dose pentamidine (7mg\/kg) for patients with cutaneous leishmaniasis caused by L. guyanensis: A pilot study","volume":"90","author":"Gadelha","year":"2015"},{"key":"b45","series-title":"BMJ Glob Health","first-page":"e000709","article-title":"Why miltefosine \u2013 A life-saving drug for leishmaniasis \u2013 Is unavailable to people who need it the most","volume":"3","author":"Sunyoto","year":"2018"},{"year":"2013","series-title":"Leishmaniasis en las Am\u00e9ricas. Recomendaciones para el Tratamiento; 2013\u2014OPS\/OMS | Organizaci\u00f3n Panamericana de la Salud","author":"Pan American Health Organization","key":"b46"},{"year":"2023","series-title":"Gu\u00eda para la Administraci\u00f3n de Terapia Intralesional con Antimoniato de Meglumina para el Tratamiento de la Leishmaniasis Cut\u00e1nea","author":"Subdirecci\u00f3n de Enfermedades Transmisibles\u2014Grupo de Enfermedades Endemoepid\u00e9micas","key":"b47"},{"key":"b48","series-title":"Cochrane Database Syst Rev","first-page":"CD004834","article-title":"Interventions for American cutaneous and mucocutaneous leishmaniasis","volume":"8","author":"Pinart","year":"2020"},{"key":"b49","series-title":"Epidemiology","first-page":"449","article-title":"Confidence limit analyses should replace power calculations in the interpretation of epidemiologic studies","volume":"3","author":"Smith","year":"1992"},{"key":"b50","series-title":"Front Pharmacol","first-page":"973","article-title":"Propensity score methods in health technology assessment: Principles, extended applications, and recent advances","volume":"10","author":"Ali","year":"2019"}],"container-title":["The American Journal of Tropical Medicine and Hygiene"],"original-title":[],"link":[{"URL":"https:\/\/www.ajtmh.org\/view\/journals\/tpmd\/111\/6\/article-p1206.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ajtmh.org\/downloadpdf\/journals\/tpmd\/111\/6\/article-p1206.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/www.ajtmh.org\/downloadpdf\/journals\/tpmd\/111\/6\/article-p1206.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T15:28:31Z","timestamp":1733326111000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ajtmh.org\/view\/journals\/tpmd\/111\/6\/article-p1206.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,4]]},"references-count":50,"journal-issue":{"issue":"6"},"URL":"https:\/\/doi.org\/10.4269\/ajtmh.24-0367","relation":{},"ISSN":["0002-9637","1476-1645"],"issn-type":[{"type":"print","value":"0002-9637"},{"type":"electronic","value":"1476-1645"}],"subject":[],"published":{"date-parts":[[2024,12,4]]}}}